EXTENDED DEADLINE FOR ABSTRACT SUBMISSION: 3rd How to Diagnose and Treat Multiple Myeloma E-CONFERENCE

 

3rd How to Diagnose and Treat
MULTIPLE MYELOMA

APRIL 15-18, 2021
E-CONFERENCE
FREE REGISTRATION

  Chairs: Hermann Einsele, Irene Ghobrial, Sonja Zweegman

---

EXTENDED DEADLINE
FOR ABSTRACTS AND CLINICAL CASES:
FEBRUARY 19th, 2021

Clinical cases and abstracts are eligible to be selected
for an oral or a poster presentation.

 

---

ABOUT THE E-CONFERENCE:

In view of continuing COVID-19 related challenges and uncertainties, this "How to Diagnose and Treat Multiple Myeloma" will be held as a virtual event.

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

ESH "How to Diagnose and Treat" conferences are disease-specific meetings that address state-of-the-art diagnostic and clinical management. They are based on the presentation and analysis of real clinical cases.  Ample time is deliberately provided for scientific discussion and interaction.

This meeting aims to share recent data and create thought-provoking academic dialogue addressing the most challenging current questions in the field of Multiple Myeloma and other plasma cell dyscrasias, from biology to clinical and therapeutic management, and future perspectives. The programme's unique format is designed to be conducive to interactive dialogue, including lectures articulated around clinical cases, controversial debates and roundtables.

The meeting will provide state-of-the-art recommendations regarding patient care and insight into controversies in the field. It should be of value to healthcare providers worldwide including MD, PhD, MD-PhD, clinical residents and PhD candidates, and allied health professionals. 




 

 SCIENTIFIC TOPICS:
- How I treat Smouldering Multiple Myeloma
- How I treat newly diagnosed Multiple Myeloma
- From risk stratification to risk-based therapy?
- Should we use MRD testing to determine therapy in multiple myeloma?
- Is there a future role of autologous stem cell transplantation?
- How I treat relapsed Multiple Myeloma
- Multiple Myeloma from the perspectives of FDA/EMEA and Foundations 
- Should every patient receive daratumumab in first line?
- You can’t be immune for immune therapy anymore
- Other plasma cell dyscrasias
- The future of Multiple Myeloma

 

---

TO ACCESS THE UPDATED PROGRAMME CLICK HERE

TO MEET THE FACULTY CLICK HERE

MORE INFORMATION
 

---

  With the support of*:
  

Major E-Conference Partners
*********

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors